Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Amicus Therapeutics' Cash from Financing Activities fell 10725.12% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 20071.93%. This contributed to the annual value of $5.1 million for FY2024, which is 9169.71% down from last year.
  • Per Amicus Therapeutics' latest filing, its Cash from Financing Activities stood at -$1.3 million for Q3 2025, which was down 10725.12% from -$400000.0 recorded in Q2 2025.
  • Amicus Therapeutics' Cash from Financing Activities' 5-year high stood at $201.1 million during Q3 2021, with a 5-year trough of -$13.3 million in Q1 2024.
  • Moreover, its 5-year median value for Cash from Financing Activities was $557000.0 (2022), whereas its average is $13.6 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Cash from Financing Activities plummeted by 19235.47% in 2022, and later soared by 682969.59% in 2023.
  • Over the past 5 years, Amicus Therapeutics' Cash from Financing Activities (Quarter) stood at -$104000.0 in 2021, then skyrocketed by 635.58% to $557000.0 in 2022, then skyrocketed by 1373.97% to $8.2 million in 2023, then plummeted by 86.64% to $1.1 million in 2024, then plummeted by 220.24% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$400000.0 for Q2 2025, and -$11.7 million during Q1 2025.